Dr. Mark Kris, MD

Claim this profile

Memorial Sloan Kettering Cancer Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
2 reported clinical trials
4 drugs studied

Area of expertise

1Lung Cancer
Mark Kris, MD has run 2 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
RET positive
AXL positive
2Non-Small Cell Lung Cancer
Mark Kris, MD has run 1 trial for Non-Small Cell Lung Cancer. Some of their research focus areas include:
RET positive
AXL positive
ROS1 positive

Affiliated Hospitals

Image of trial facility.
Memorial Sloan Kettering Cancer Center

Clinical Trials Mark Kris, MD is currently running

Image of trial facility.

Cabozantinib

for Non-Small Cell Lung Cancer

The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity. A phase II study looks at how effective a medication is at treating a specific type of cancer and collects information on the side effects of the study treatment. RET, ROS1, or NTRK fusion or increased MET or AXL activity gene leads to lung cancer cell growth. Cabozantinib is an oral medicine that inhibits of RET, ROS1, NTRK, MET, and AXL. In addition, this drug interferes with other cell pathways that also cause cancer cells to grow, form new blood vessels, and spread to other organs of the body. The goal of using cabozantinib is to shrink the cancer and to prevent it from growing Cabozantinib has been studied and shown to cause cancer shrinkage in other cancers such as medullary thyroid cancer and prostate cancer. We thus have a good idea of what side-effects it causes and can anticipate them.
Recruiting1 award Phase 29 criteria

More about Mark Kris, MD

Clinical Trial Related6 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 1 Active Clinical Trial
Treatments Mark Kris, MD has experience with
  • Cabozantinib
  • Etoposide
  • Osimertinib
  • Platinum
Breakdown of trials Mark Kris, MD has run
Lung Cancer
Non-Small Cell Lung Cancer

Other Doctors you might be interested in

Urvi Shah, MDMemorial Sloan Kettering Nassau (All Protocol Activities)
Roni Tamari, MDMemorial Sloan Kettering Cancer Center
Shari Goldfarb, MDMemorial Sloan Kettering Cancer Center

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Kris, MD specialize in?
Mark Kris, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are RET positive.
Is Mark Kris, MD currently recruiting for clinical trials?
Yes, Mark Kris, MD is currently recruiting for 1 clinical trial in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Mark Kris, MD has studied deeply?
Yes, Mark Kris, MD has studied treatments such as Cabozantinib, Etoposide, Osimertinib.
What is the best way to schedule an appointment with Mark Kris, MD?
Apply for one of the trials that Mark Kris, MD is conducting.
What is the office address of Mark Kris, MD?
The office of Mark Kris, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security